sampatrilat

Known as: N-(1-(2-carboxy-3-(N(2)-mesyllysylamino)propyl)-1-cyclopentylcarbonyl)tyrosine 
 
National Institutes of Health

Related topics

Related topics

5 relations

Broader (3)

MesylatesProtease InhibitorsTyrosine

Narrower (1)

UK 81,252
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Crystal structures of sampatrilat and sampatrilat‐Asp in complex with human ACE – a molecular basis for domain selectivity
Angiotensin-1-converting enzyme (ACE) is a zinc metallopeptidase that consists of two homologous catalytic domains (known as nACE… (More)
  • table 1
  • table 2
  • figure 1
  • figure 3
  • figure 2
Is this relevant?
2016
2016
The Dynamic Nonprime Binding of Sampatrilat to the C-Domain of Angiotensin-Converting Enzyme
Sampatrilat is a vasopeptidase inhibitor that inhibits both angiotensin I-converting enzyme (ACE) and neutral endopeptidase. ACE… (More)
Is this relevant?
2009
2009
OE-326 A Multi-Targeting Chronic Neurohumoral Therapy with Sampatrilat in Experimental Congestive Heart Failure : Neurohumoral, Renal and Clinical Actions(OE55,Heart Failure (Treatment) 2 (M),Oral…
 
Is this relevant?
2003
2003
Beneficial effects of sampatrilat, a novel vasopeptidase inhibitor, on cardiac remodeling and function of rats with chronic heart failure following left coronary artery ligation.
Sampatrilat is a novel vasopeptidase inhibitor that may offer a greater benefit than traditional angiotensin-converting enzyme… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
2002
2002
Sampatrilat Shire.
Sampatrilat is a dual inhibitor of neutral endopeptidase (NEP) and angiotensin converting enzyme (ACE), which is under… (More)
Is this relevant?
Review
2002
Review
2002
Vasopeptidase inhibitors.
Vasopeptidase inhibitors are a new class of drugs that have dual inhibitory effects on two key enzymes involved in the metabolism… (More)
Is this relevant?
1999
1999
Sustained antihypertensive actions of a dual angiotensin-converting enzyme neutral endopeptidase inhibitor, sampatrilat, in black hypertensive subjects.
Our objective was to evaluate the safety and antihypertensive efficacy of sampatrilat, a novel dual inhibitor of both angiotensin… (More)
Is this relevant?
1998
1998
Combined inhibition of neutral endopeptidase and angiotensin-converting enzyme by sampatrilat in essential hypertension.
BACKGROUND The antihypertensive response to angiotensin-converting enzyme (ACE) inhibitors may be attenuated by a compensatory… (More)
Is this relevant?
1998
1998
Clinical analysis of sampatrilat, a combined renal endopeptidase and angiotensin-converting enzyme inhibitor II: assay in the plasma and urine of human volunteers by dissociation enhanced lanthanide…
Sampatrilat is a dual inhibitor of angiotensin converting enzyme (ACE) and neutral endopeptidase (NEP) under development for the… (More)
Is this relevant?
1996
1996
Renal effects of concurrent E-24.11 and ACE inhibition in the aorto-venocaval fistula rat.
1. The present studies compare the early renal response to (a) an endopeptidase-24.11 (E-24.11) inhibitor (candoxatrilat) (b) an… (More)
Is this relevant?